

15 May 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J's Duato on the importance of diversity; Teva's views on its new risperidone launch; Almirall's hopes for lebrikizumab; Biogen's Viehbacher questions the need for spending on weight loss drugs; and Citeline's annual R&D review looks at the current state of the global biopharma pipeline.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 May 2023, including: [Johnson & Johnson's](#) Duato on the importance of diversity; [Teva Pharmaceutical Industries Ltd.](#)'s views on its new risperidone launch; [Almirall SA](#)'s hopes for lebrikizumab; [Biogen, Inc.](#)'s Viehbacher questions the need for spending on weight loss drugs; and *Citeline's* annual R&D review looks at the current state of the global biopharma pipeline.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[J&J CEO On Stereotypes, Innovation Secret Sauce And Kenvue](#)" - Scrip, 8 May, 2023.)

(Also see "[Teva Expects To Carve Out Sizable Niche For Uzedry In Antipsychotic Market](#)" - Scrip, 10 May, 2023.)

(Also see "[Almirall On Alert As Lebrikizumab Approval Date Approaches](#)" - Scrip, 9 May, 2023.)

(Also see "[Biogen CEO Poses Million Dollar Question – Do We Need To Spend On Weight Loss](#)"

[Drugs?](#) - Scrip, 10 May, 2023.)

(Also see "[Oncology's Hold Over The Pharma Pipeline Increases As Growth Slows](#)" - Scrip, 8 May, 2023.)

[Click here to explore this interactive content online](#) 